Funding of £5m will create new jobs in Norfolk

Published: 28-Jan-2010
Manufacturing Research & Development Finance Pharmaceutical

Thirty new laboratories and offices for 300 research scientists are to be built in Norfolk, UK

Thirty new laboratories and offices for 300 research scientists are to be built in Norfolk, UK with £5m of funding from a partnership including the Biotechnology and Biological Sciences Research Council (BBSRC).

The new development will be based at Norwich Science Park and provide facilities for start-up and expanding businesses.

BBSRC will provide £500,000 as well as the land and buildings to host the new facilities, with £1.4m coming from the East of England Development Agency (EEDA), £1m from the Greater Norwich Development Partnership (GNDP), £500,000 from NRP partner the University of East Anglia (UEA), and the remainder from other NRP partners.

The new facilities, to be opened in July, will be managed by a new joint venture company called Colney Innovations (CIL).

David Parfrey, BBSRC director of finance and director of CIL, said: "The research carried out by the 2,000 scientists already working at Norwich Science Park is world-class and it makes absolute sense to create a facility on this site where the results of such research can be taken through to applications."

Prof Douglas Kell, chief executive of BBSRC, added: "The Norwich Research Park is home to three world-class BBSRC institutes: the John Innes Centre, the Institute of Food Research and The Genome Analysis Centre. This new facility will play a key role in helping our scientists, and others, to translate their excellent science into products to benefit the economy and people of the UK."




See more

You may also like

Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

Read more
This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    Procurement as a strategic business enabler How Alkermes unlocked $30m in project cost savings with JAGGAER
  2. AFYREN obtains FSSC 22000 certification for industrial site The AFYREN NEOXY plant is now certified for the production and processing of biobased monocarboxylic acids and their derivatives for the food and feed industries, a guarantee of trust and performance for customers
  3. Top 10 tips for optimal rotary evaporation with Vacuubrand Labtex shares: "In the UK, we supply a comprehensive range of high-quality laboratory and instrumentation vacuum pumps from our trusted partners at Vacuubrand - world leaders in vacuum technology!"
  4. Johnson & Johnson files FDA application for IMAAVY in wAIHA Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
  5. You need to be a subscriber to read this article.
    Click here to find out more.
    Landmark NHS‑Galleri trial cuts Stage IV cancers and boosts early detection across England NHS‑Galleri trial shows multi‑cancer blood test sharply reduces late‑stage diagnoses and boosts early detection—possibly signalling a structural change in cancer drug demand, supply chain planning and long-term oncology production strategy

Upcoming event

DCAT Week

23–26 March 2026 | Conference | New York, US See all

You may also like

Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs
Research & Development

OSE Immunotherapeutics receives positive IDMC review for Phase III ARTEMIA trial

OSE Immunotherapeutics SA has received a second positive recommendation from the Independent Data Monitoring Committee to continue its Phase III ARTEMIA trial of Tedopi in advanced non-small cell lung cancer
Research & Development

Vilnius University scientists reveal new role for CRISPR-Cas9 in bacterial immunity

The researchers report in Molecular Cell that the CRISPR-Cas9 protein plays a previously unknown role in selecting and integrating viral DNA fragments during bacterial immune memory formation
Research & Development

Lilly’s Orforglipron beats oral semaglutide in Phase III ACHIEVE-3 trial with superior weight loss

Head-to-head data published in The Lancet show Eli Lilly's oral GLP-1 candidate orforglipron delivered significantly greater HbA1c reductions and weight loss than oral semaglutide in adults with type 2 diabetes, supporting global regulatory submissions
Manufacturing

Viatris to cut 10% of its global workforce after Indian plant fire

Viatris has lowered its profit outlook for 2026 after a fire in February shut down a key plant in Nashik, India. Despite this, the company reported stronger-than-expected revenue and announced a restructuring plan
Manufacturing

GEA opens new technology centre in Germany

The opening of the new technology centre for pharmaceutical freeze-drying systems will strengthen the supplier's position in the growing pharmaceutical applications market
Finance

Heligan Group report: UK healthcare M&A remains resilient

A new report from the investment group has highlighted the healthcare field as being a "defensive, structurally supported sector"
Subscribe now